Stay updated on EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Sign up to get notified when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.

Latest updates to the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe clinical trial record for the EPIK-B2 study is displayed, describing alpelisib with trastuzumab and pertuzumab for advanced HER2-positive breast cancer. It includes study design, participation criteria, locations, outcome measures, and information about sharing participant-level data.SummaryDifference61%

- Check14 days agoChange DetectedThe footer’s site revision indicator changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedAn NIH-wide banner announces transition updates and says federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI). The study page itself still displays a 403 error.SummaryDifference1%

- Check28 days agoChange DetectedThe revision identifier in the footer changes from v3.7.1 to v3.7.2; the study record remains inaccessible.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content with a generic error page, which blocks access to the study details.SummaryDifference20%

Stay in the know with updates to EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.